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When becomes more in fact less?The principles ‘in dubio abstine’ and ‘primum non
nocere’ are as least as old as the language they are written
in, and have been made very concrete in criticisms on iatro-
genesis, medicalization, polypharmacy and polypragmasy.
Clinical decision analysis [1], health technology assess-
ment, and critical appraisal of clinical evidence [2] have
provided useful methods to translate these principles in
better health care by avoiding useless and potentially harm-
ful intervention.
To day, these principles are also applied in research
practice, as research resources are scarce, and superfluous
research is not only a waste but may also push valuable re-
search aside[3e5]. Moreover, useless research implies ex-
posing research subjects to the burden and sometimes risk
of being studied without justification. We must therefore al-
so make progress in designing methods to recognize and
avoid research studies without added value.
These issues are addressed in various contributions.
Stalpers et al. give an update of methods that can help
clinicians to reduce diagnostic testing that has no added
value and may even be harmful, and further elaborated
the concepts ‘threshold approach to clinical decision mak-
ing’ [6,7] and ‘indication area of a diagnostic test’[8]. They
developed a decision analytical model in which ‘testing’
and ‘no testing’ were compared, in order to identify the in-
dication area of prior probabilities wherein use of a diag-
nostic test results in a net gain. They illustrate their
approach, using a freely available website-based calculator
with graphical representation developed for his purpose,
with various clinical examples. In a second paper,
Stalpers et al. investigate whether indication area and max-
imum diagnostic gain are robust measures in relation to test
dependence [9], alternative physician’s heuristics, and vary-
ing patient’s utilities. Based on mathematical, decision
heuristic, and utility analysis - and again supported by
examplesethe authors conclude that indication area and
the maximum diagnostic gain are indeed robust measures
of test performance.
In research decision making, a key question is whether
adding a new study to the already available evidence,
would change conclusions. Chevance c.s. investigated
whether robustness of an existing meta-analysis can justify
decisions on whether to conduct an additional study on the
same research question. They present a contour plot assess-
ment of meta-analysis, using the example of the potential
impact of an additional study on the effect of statin usehttp://dx.doi.org/10.1016/j.jclinepi.2015.08.014
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ture single studies of common sample size will not consid-
erably change the direction and magnitude of the currently
evident effect estimates. They conclude that the illustrated
contour approach can indeed guide decisions on whether to
conduct additional studies on a relevant research question,
and recommend that it should become a standard tool for
the assessment of meta-analyses.
Another pertinent issue is whether noninferiority
studiesein order to demonstrate whether a new treatment
is not substantially less effective than an already available
treatment - really have added value. Claims can be that
the new treatment may have an advantage as to burden of
treatment, side effects, and cost. Gayet-Ageron and her
team explored characteristics of clinical trials that may in-
fluence the choice of the ‘noninferiority margin’ (NIM): the
largest loss of effectiveness that is clinically negligable to
establish noniferiority. They conducted an experimental
survey among corresponding authors of randomized con-
trolled trials indexed in Medline, asking their opinions on
two hypothetical studies. The authors found that mortality
as a primary outcome, low baseline risk with standard treat-
ment, a less costly new treatment and fewer side effects
were associated with choosing smaller NIMs. Interestingly,
the population age group (adults vs. children) showed no
effect on the choice of the NIM. They recommend that
the process to determine the NIM should be explictly based
on clinically relevant factors, such as identified in their
survey.
Although Gayet-Ageron did not find population age
group to play a role in choosing the NIM, equivalence of
effects of interventions among children and adults cannot
a priori be assumed [10]. Janiaud et al. evaluated whether
the therapeutic benefit in placebo controlled randomized
clinical trials is different for children and adults. Based
on a review of meta-analyses of trials with separate results
for adults and children, for 14 of 124 drugs they found dif-
ferent treatment benefits for trials in adults compared with
trials in children. The authors recommend that data on dose
adjustment and age groups should be better reported to in-
vestigate extrapolation from adults to children.
Speaking about extrapolation, another question is
whether systematic reviews of clinical trials consider ap-
plicability of study results for primary care. This was ex-
plored by Missiou and Tatsioni. In a sample from the
Cochrane Database for Systematic Reviews over the periodess article under the CC BY-NC-ND license (http://creativecommons.org/
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comment on applicability of results for primary care. It was
concluded that, in order to support evidence synthesis rele-
vant to primary care, review authors must do additional
work to assess the applicability and relevance of study re-
sults to primary care practice. The authors suggest prospec-
tive registration of trials in primary care including specific
information on applicability. In a commentary, van Weel
emphasizes that in the translation of research to practice,
the context in which patients are encountered should be ad-
dressed, not only considering health status but also socioe-
conomic circumstances, cultural and religious features,
social determinants of health, and the actual function in
which the encounter between patient and professional takes
place. The closer to the practice setting research data are
collected, the more straightforward the translation is.
Vucic and colleagues analyzed whether protocols of
Cochrane systematic reviews address data extraction from
figures in included trials. After screening the protocols
published between May 2013 and May 2014, the authors
found that very few protocols mention data extraction
from figures, and when mentioned the methods for extrac-
tion are unclear. They recommend to address this issue in
the Cochrane Handbook and the methodological standards
for reviews.
Less is not more when data in longitudinal studies are
missing. This is an ongoing challenge researchers have to
deal with, first and foremost to avoid missing data as much
as possible, and in addition to minimize the impact of miss-
ing data on study results. Jones c.s. compared seven meth-
ods for the analysis of longitudinal studies with missing
data due to drop-out or death, based on an longitudinal
study of elderly women. While ignoring missing data
resulted in biased estimates, it was shown that appropriate
analytic methodology depends on the target of inference
and the missing data mechanism. Therefore, for the primary
analysis a method should be used that is robust tot he most
plausible missing data mechanism.
To adjust for confounding in observational research, pro-
pensity score (PS) and instrumental variable (IV) analyses
are often used. These techniques are used also simulta-
nously in observational studies evaluating interventions.
In a review of these studies Laborde-Casterot and co-
workers analyzed the agreement between PS and IV results.
They found that discrepancies are frequent. Researchers
should carefully consider their analytic choices and readers
must be cautious when interpreting results. The authors rec-
ommend further studies to clarify the roles of the two meth-
ods and to investigate the indications for each method.
A good balance of collecting sufficient but not too many
data must also be found for clinimetric instruments.
Hutchings et al. developed and validated the Gastrointestinal
SymptomRating Questionnaire (GSRQ) for patients with lu-
minal gastrointestinal symptoms referred to secondary careand in particular where no diagnosis has been made. The in-
strument was developed and piloted on patients with a known
GI disorder, and tested in a sample of trial patients. The val-
idation is reported to be successful in measuring health re-
lated quality of life (HRQL) in various GI conditions and
where a formal diagnosis has not been established. The au-
thors recommend the GSRQ to help monitor HRQL in pa-
tients before a diagnosis has been made and during the
longitudinal course of their disease. G€artner and co-authors
validated the Labor and Delivery Index (LADY-X), a new
delivery-specific utility measure reflecting the course of la-
bor and birth, in a test-retest design among women whowere
surveyed online in the postpartum period. The LADY-X
showed good reliability and construct validity and discrimi-
nated between groups. It may fulfill the need for a utility
measure for cost-effectiveness studies for perinatal interven-
tions. The comparability of the English, Chinese and Malay
versions of the EQ-5D-5 L response labels, describing mild
or extreme health problems, was investigated Luo and
colleagues in primary care in Singapore. Interpretation and
use of these labels varied among Singaporeans using differ-
ent language versions of the instrument. They recommend
further studies on ways to reduce the variations and to in-
crease the cross-cultural measurement equivalence. Another
cross-cultural adaptation was performed by Wei and
collaborators, who aimed to obtain an adapted and validated
Chinese version of the Tampa Scale for Kinesiophobia (SC-
TSK).Based on their study inLBPpatients, the authors found
good internal consistency, test-retest reliability, and con-
struct validity. They conclude that the SC-TK can be consid-
ered a valid instrument for Chinese-speaking patients in
mainland China. Kopec and his group developed and vali-
dated a multiattribute health (MAHU) utility scoring method
for the CAT (Computer adaptive testing)-SD-QOL, measur-
ing five domains of health-related quality of life. The empiri-
cal validation was carried out among retired persons. The
study provided preliminary evidence to support the validity
of the MAHU scoring system for the CAT-SD-QOL, which
may be useful for economic evaluation studies. Future appli-
cations in clinical studies will provide further insight in the
performance of the system.
The randomized registry trial, which is a trial built up on
the structure of an existing registry of patients, can be use-
ful to investigate volume-outcome relationships and learn-
ing curve effects, while better representing clinical reality,
avoiding selection bias and promoting efficiency. This is
highlighted by Pieper and Neugebauer, who also discuss
the preconditions registries have to meet for this purpose.
Papavasilou and Payne address another challenge when
trying to observe reality: when studying the (evolution of)
prevalence of continuous sleep sedation until death, as a
type of end-of-life sedation, a problem is the gray area be-
tween sleep sedation until death and euthanasia. They dis-
cuss this issue in the context of the legal development in
1119Editorial / Journal of Clinical Epidemiology 68 (2015) 1117e1119various countries, potential sources of bias, and the need to
promote the integrity of science, the art of medicine, and
the betterment of public health.
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